CRISPR-Engineered Immunotherapy for Metastatic GI Tract Cancers
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Immunotherapy for Advanced Pancreatic Cancer and Other Solid Tumors
Researchers are testing the use of tumor-infiltrating lymphocytes, a type of immunotherapy, against advanced pancreatic cancer.
Overcoming Challenges to Vaccine Immunotherapy
Modern immunology shows that Coley’s principles of immune stimulation were indeed on target, and today the field of cancer immunology…
Chemotherapy, Immunotherapy, and Radiation for Locally Advanced Pancreatic Cancer
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
Two Types of Immunotherapy for Surgically Removable Pancreatic Cancer
A clinical trial compares the effectiveness of two different types of immunotherapy with standard treatment after pancreatic cancer surgery.
Comparing the Effectiveness of Vaccine Therapy With or Without Additional Immunotherapy
Exploring the effectiveness of the immunotherapy combination of cancer vaccines and a checkpoint blockade drug against metastatic pancreatic cancer.